• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Importance of genotyping patients for HLA-C*06:02: it provides not only pharmacogenetics implication in response to biologics drugs but also drug survival and drug-related costs information.对患者进行HLA-C*06:02基因分型的重要性：它不仅提供了对生物制剂药物反应的药物遗传学意义，还提供了药物生存期和药物相关成本信息。
Ann Transl Med. 2020 Aug;8(15):971. doi: 10.21037/atm.2020.04.05.
2
A clinical approach to pharmacogenetics.药物遗传学的临床应用方法。
Neth J Med. 2013 Apr;71(3):145-52.
3
Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe.临床实践中药物基因组学的成本效益：欧洲急性淋巴细胞白血病中硫嘌呤甲基转移酶基因分型的案例研究
Pharmacogenomics. 2006 Jul;7(5):783-92. doi: 10.2217/14622416.7.5.783.
4
Human leukocyte antigen (HLA) and pharmacogenetics: screening for HLA-B*57:01 among human immunodeficiency virus-positive patients from southern Alberta.人类白细胞抗原（HLA）和药物遗传学：在艾伯塔省南部的人类免疫缺陷病毒阳性患者中筛选 HLA-B*57:01。
Hum Immunol. 2012 Feb;73(2):164-7. doi: 10.1016/j.humimm.2011.12.002. Epub 2011 Dec 8.
5
Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future.细胞色素P450的药物遗传学及其在药物治疗中的应用：过去、现在与未来
Trends Pharmacol Sci. 2004 Apr;25(4):193-200. doi: 10.1016/j.tips.2004.02.007.
6
Cost-effectiveness Analysis for Genotyping before Allopurinol Treatment to Prevent Severe Cutaneous Adverse Drug Reactions.别嘌醇治疗前基因分型预防严重皮肤药物不良反应的成本效益分析
J Rheumatol. 2017 Jun;44(6):835-843. doi: 10.3899/jrheum.151476. Epub 2017 Apr 1.
7
The emerging role of pharmacogenomics in biologics.药物基因组学在生物制剂中的新兴作用。
Clin Pharmacol Ther. 2007 Oct;82(4):466-71. doi: 10.1038/sj.clpt.6100334. Epub 2007 Aug 22.
8
The Importance of New Generation Sequencing (NGS) HLA Typing in Renal Transplantation-Preliminary Report.新一代测序（NGS）HLA分型在肾移植中的重要性——初步报告
Transplant Proc. 2018 Jul-Aug;50(6):1605-1615. doi: 10.1016/j.transproceed.2018.05.005. Epub 2018 Jun 21.
9
Genotyping HLA-B*5801 for Allopurinol-Induced Severe Cutaneous Adverse Reactions: An Accurate and Prompt Method.通过基因分型HLA - B*5801预测别嘌醇诱导的严重皮肤不良反应：一种准确且快速的方法。
Clin Transl Sci. 2015 Dec;8(6):834-6. doi: 10.1111/cts.12365. Epub 2015 Dec 14.
10
Pharmacogenetics in clinical dermatology.临床皮肤病学中的药物遗传学。
Br J Dermatol. 2002 Jan;146(1):2-6. doi: 10.1046/j.1365-2133.2002.04466.x.

本文引用的文献

1
Clinical Features and Genetic Polymorphism in Chinese Patients with Erythrodermic Psoriasis in a Single Dermatologic Clinic.单皮肤科诊所中红皮病型银屑病中国患者的临床特征及基因多态性
Mol Diagn Ther. 2020 Feb;24(1):85-93. doi: 10.1007/s40291-019-00441-x.
2
Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience.乌司奴单抗治疗中重度斑块状银屑病：八年真实世界经验。
Expert Opin Biol Ther. 2020 Jan;20(1):95-104. doi: 10.1080/14712598.2020.1684472. Epub 2019 Oct 30.
3
The contribution of IL-17 to the development of autoimmunity in psoriasis.IL-17 对银屑病自身免疫发病机制的影响。
Innate Immun. 2019 Aug;25(6):337-343. doi: 10.1177/1753425919852156. Epub 2019 May 24.
4
Association of HLA-C*06:02 Status With Differential Response to Ustekinumab in Patients With Psoriasis: A Systematic Review and Meta-analysis.HLA-C*06:02 等位基因状态与银屑病患者乌司奴单抗疗效差异的相关性：系统评价和荟萃分析。
JAMA Dermatol. 2019 Jun 1;155(6):708-715. doi: 10.1001/jamadermatol.2019.0098.
5
HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis.HLA-C*06:02 基因型是银屑病生物治疗反应的预测性生物标志物。
J Allergy Clin Immunol. 2019 Jun;143(6):2120-2130. doi: 10.1016/j.jaci.2018.11.038. Epub 2018 Dec 20.
6
Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence.生物制剂治疗银屑病的药物生存：真实世界证据的荟萃分析。
Sci Rep. 2018 Oct 30;8(1):16068. doi: 10.1038/s41598-018-34293-y.
7
Limited clinical utility of HLA-Cw6 genotyping for outcome prediction in psoriasis patients under ustekinumab therapy: a monocentric, retrospective analysis.乌司奴单抗治疗的银屑病患者中HLA-Cw6基因分型对结局预测的临床应用有限：一项单中心回顾性分析
Psoriasis (Auckl). 2018 Mar 23;8:7-11. doi: 10.2147/PTT.S161437. eCollection 2017.
8
Psoriasis pharmacogenetics: HLA-Cw*0602 as a marker of therapeutic response to ustekinumab.银屑病药物遗传学：HLA - Cw*0602作为乌司奴单抗治疗反应的标志物
Eur J Dermatol. 2017 Oct 1;27(5):528-530. doi: 10.1684/ejd.2017.3071.
9
Drug survival of biologic treatments in psoriasis: a systematic review.银屑病生物治疗的药物生存期：一项系统评价
J Dermatolog Treat. 2018 Aug;29(5):460-466. doi: 10.1080/09546634.2017.1398393. Epub 2017 Nov 10.
10
Characteristics of patients receiving ustekinumab compared with secukinumab for treatment of moderate-to-severe plaque psoriasis - nationwide results from the DERMBIO registry.与司库奇尤单抗相比，接受乌司奴单抗治疗中重度斑块型银屑病患者的特征 - 来自 DERMBIO 登记处的全国性结果。
J Eur Acad Dermatol Venereol. 2017 Jul;31(7):1183-1187. doi: 10.1111/jdv.14200. Epub 2017 Mar 29.

Importance of genotyping patients for HLA-C*06:02: it provides not only pharmacogenetics implication in response to biologics drugs but also drug survival and drug-related costs information.

作者信息

Talamonti Marina, Galluzzo Marco

机构信息

Dermatology Unit, Fondazione Policlinico Tor Vergata, Rome, Italy.

Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy.

出版信息

Ann Transl Med. 2020 Aug;8(15):971. doi: 10.21037/atm.2020.04.05.

DOI:10.21037/atm.2020.04.05
PMID:32953771
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7475382/
Abstract
摘要